Instylla Logo

Materializing Solutions

Instylla delivers next-generation liquid embolics for interventional radiology, with initial clinical applications in interventional oncology and peripheral hemostasis.

Latest news

Instylla Announces Enrollment of Initial Patients in the Embrace Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial

March 30, 2021

BEDFORD, Mass., March 30, 2021 /PRNewswire/ — Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embolotherapy, today announced the enrollment of the first patients in the Embrace Hydrogel Embolic System (HES™) global randomized clinical trial for the treatment of hypervascular tumors. As demonstrated previously in the completed First-in-Human (FIH) study, […]

Read More